1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demet

The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demet

  1. Anonymous
    Biopharm Drug Dispos. 1994 May;15(4):263-72.

    Abstract

    The pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam (NDMAD) were evaluated in twelve healthy non-smokers (NS) and twelve smokers (S, > or = 20 cigarettes/day) following a single 60 mg dose of adinazolam mesylate sustained-release tablets in an open-label, parallel-group design. Venous blood samples were collected for up to 36 h following drug administration and assayed for adinazolam and NDMAD by HPLC. Urine samples were also collected and assayed for NDMAD by HPLC. Psychomotor performance was measured using the Neurobehavioral Evaluation System. No significant differences were observed in adinazolam oral clearance (51.8 +/- 25.8 versus 48.2 +/- 14.01 h-1) or peak adinazolam plasma concentrations (Cmax) (93.3 +/- 31.8 versus 90.4 +/- 18.0 ng ml-1) between groups. NDMAD AUC (2541 +/- 457 versus 2798 +/- 447 ng h ml-1) and Cmax (173 +/- 30.3 versus 175 +/- 26.9 ng ml-1) did not differ significantly between groups. NDMAD renal clearance was significantly lower in smokers than non-smokers (8.7 +/- 0.7 versus 10.7 +/- 2.71 h-1; p < 0.05), but the clinical significance of this observation is unclear. Marginally significant differences were seen between groups in the symbol-digit substitution and digit span (forward) tasks. The results suggest that smoking has little effect on adinazolam and NDMAD pharmacokinetics or psychomotor effects but that smoking may slightly decrease renal clearance of NDMAD.